



Science. Commitment. Compassion.

The mission of Bristol-Myers Squibb Company is to extend and enhance human life. The Company is dedicated to conducting research and developing drugs designed to aid in the fight against 10 core disease states. Chronic hepatitis represents one of the core areas of focus.

BMS is committed to educating the public, patient advocates and physicians regarding the seriousness of infectious diseases, such as chronic hepatitis B infection. More than one million people worldwide die each year of complications associated with chronic hepatitis B infection. BMS is dedicated to finding new therapies for patients, and has an active discovery program for chronic hepatitis B.

BMS is dedicated to the fight against several disease states including HIV/AIDS, oncology, atherosclerosis/thrombosis, diabetes, obesity, rheumatoid arthritis and Alzheimer's disease. BMS consistently pursues the best science possible and continually demonstrates commitment and compassion for people living with these diseases. Now, BMS has extended this commitment and is developing a treatment for chronic hepatitis B.

Science

BMS aims to provide novel, clinically proven and safe therapeutic options at key stages of diseases. Several clinical studies are currently underway to investigate the treatment of hepatitis B. BMS also has an active discovery program underway for hepatitis C.

Commitment

BMS is dedicated to providing therapeutic options which support the needs of our customers (physicians, advocates, patients, etc.). According to the World Health Organization, more than half a million people worldwide die each year from primary liver cancer, and up to 80 percent of liver cancers are due to hepatitis B.

Compassion

BMS empathizes with patients living with diseases and works to respond to their needs. The following programs are examples of the BMS commitment to the community:

- **Hepatitis B Rural Vaccination Education Project** in China is a program initiated by Bristol-Myers Squibb Foundation, Chinese Liver Foundation and the Chinese Ministry of Health. The project is designed to increase vaccination rates among newborns in six impoverished counties in China's Shan'xi and Gansu provinces. The Bristol-Myers Squibb Foundation has provided a grant of \$510,000 to support this project.
- **Chronic Hepatitis B Educational Initiative:** In May of 2004, BMS launched a nationwide educational initiative, "AIM for the B: Awareness, Involvement and Mobilization for Chronic Hepatitis B," designed to raise awareness of chronic hepatitis B and the need for active involvement on the part of health care providers and patients in the treatment of this disease.
- **SECURE THE FUTURE™** is a five-year, \$115 million commitment to help develop local, sustainable programs to address the devastating impact of HIV/AIDS in sub-Saharan and West African nations. The initiative's two-pronged approach provides both medical research and community outreach and education grants. For more information visit www.securethefuture.com.

- **Susan G. Komen New Jersey Race for the Cure:** BMS will host nearly 25,000 people from New Jersey communities at the company's Lawrenceville, N.J., campus for the Susan G. Komen New Jersey Race for the Cure. The race, sponsored annually by the Breast Cancer Resource Center (BCRC) of the YWCA of Princeton, is expected to raise \$1.3 million for breast cancer research, screening and education. BMS has hosted the New Jersey Race for the Cure at its Lawrenceville campus for five consecutive years.
- **American Diabetes Association's (ADA) School Walk for Diabetes** is a step in the right direction toward diabetes awareness. BMS has teamed up with the ADA to help a number of central New Jersey schools get on the path to raise awareness about diabetes. The campaign educates students, teachers and parents about diabetes and also raises money for the ADA for research and education. The BMS challenge will encourage schools to host school walks and help increase their students' knowledge about diabetes.
- **BMS Foundation** has provided nearly \$13 million in unrestricted funding to research institutions since 1991 as part of the Infectious Diseases Research Grants Program.
- **Bristol-Myers Squibb U.S. Patient Assistance Foundation** provides free medicines that have been donated by BMS to low-income patients who do not qualify for prescription drug assistance through public or private sources. Enrollment in the program is initiated by the patient's physician.

For more information on BMS and the Company's mission to extend and enhance human life, visit www.bms.com.